James G. Marken
2013
In 2013, James G. Marken earned a total compensation of $1.5M as Vice President, Operations at ANI Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $73,805 |
|---|---|
| Option Awards | $718,275 |
| Salary | $131,433 |
| Stock Awards | $530,994 |
| Total | $1,454,507 |
Marken received $718.3K in option awards, accounting for 49% of the total pay in 2013.
Marken also received $73.8K in non-equity incentive plan, $131.4K in salary and $531K in stock awards.
Rankings
In 2013, James G. Marken's compensation ranked 5,071st out of 12,286 executives tracked by ExecPay. In other words, Marken earned more than 58.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,071 out of 12,286 | 59th |
Division Manufacturing | 1,748 out of 4,612 | 62nd |
Major group Chemicals And Allied Products | 503 out of 1,462 | 66th |
Industry group Drugs | 357 out of 1,156 | 69th |
Industry Pharmaceutical Preparations | 286 out of 890 | 68th |
Source: SEC filing on April 14, 2016.
Marken's colleagues
We found six more compensation records of executives who worked with James G. Marken at ANI Pharmaceuticals in 2013.
2013
Arthur Przybyl
ANI Pharmaceuticals
Chief Executive Officer
2013
Charlotte Arnold
ANI Pharmaceuticals
Chief Financial Officer
2013
Stephen Simes
ANI Pharmaceuticals
Chief Executive Officer
2013
Robert Schrepfer
ANI Pharmaceuticals
Vice President, New Business Development and Contract Manufacturing
2013
Phillip Donenberg
ANI Pharmaceuticals
Chief Financial Officer
2013
Robert Jamnick
ANI Pharmaceuticals
Vice President, Quality and Product Development
News
ANI Pharmaceuticals CEO Nikhil Lalwani's 2021 pay jumps 76% to $6.5M
March 25, 2022
ANI Pharmaceuticals CEO Nikhil Lalwani receives $3.7M in 2020
April 29, 2021
ANI Pharmaceuticals CEO Arthur Przybyl's 2019 pay jumps 39% to $5.8M
April 23, 2020
ANI Pharmaceuticals CEO Arthur Przybyl's 2018 pay rises 17% to $4.2M
April 4, 2019